Psychiatry Residency MCG

ment for patients with residual schizophrenia. A randomized controlled trial of adjunctive tocilizumab in schizophrenia. NARSAD Independent Investigator Grant
PI: Brian Miller, M.D., Ph.D., MPH

A randomized controlled trial of adjunctive siltuximab in schizophrenia. Stanley Medical Research Institute
PI: Brian Miller, M.D., Ph.D., MPH

A potential state and relapse predictive marker in schizophrenia. National Institute of Mental Health
PI: Brian Miller, M.D., Ph.D., MPH

BDNF/TrkB: a possible therapeutic target for schizophrenia. National Institute of Mental Health
PI: Anilkumar Pillai, Ph.D

Paliperidone, mimicking paliperidone palmitate administration on brain BDNF: implications for relapse and neuroplasticity in schizophrenia. Ortho Mc-Neil Janssen Pharma
PI: Anilkumar Pillai, Ph.D

A phase II randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 52-week treatment period as an early intervention in patients with attenuated psychosis syndrome. Improving cognition via exercise in schizophrenia
National Institute of Mental Health (NIMH)
PI: Joseph McEvoy, M.D. Metformin and Lorcaserin for weight loss in people with schizophrenia
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
PI: Joseph McEvoy, M.D. A phase II, 12-week, randomized, double-blind, placebo-controlled, parallel study to evaluate efficacy, safety, tolerability, and pharmacokinetics of the three dose levels of TAK-831 in adjunctive treatment of adult patients with negative symptoms of schizophrenia
Millennium Pharmaceuticals, Inc. Phase II, A randomized, double-blind, multiple-dose, placebo-controlled study to evaluate the safety and efficacy of BIIB104 in subjects with cognitive impairment associated with schizophrenia
Biogen MA, Inc.